|
Millennium Predictive Medicine and BD Enter Into Licensing Agreement In The Area of Colon Cancer Diagnostics MILLENNIUM PHARMACEUTICALS, INC. LOGO Millennium Pharmaceuticals, Inc. logo. (PRNewsFoto)[DM] CAMBRIDGE, MA USA 12/20/1999 - New Agreement in Oncology Reflects Success of Existing Alliance - CAMBRIDGE, Mass., July 18 /PRNewswire/ -- Millennium Predictive Medicine, Inc. (MPMx), a wholly-owned subsidiary of Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced they have entered into a licensing agreement with BD (Becton Dickinson and Company) (NYSE: BDX) in the area of colon cancer diagnostics. Under the terms of the agreement, BD has paid MPMx a licensing fee in exchange for certain research and development rights to select diagnostic markers and related intellectual property developed by MPMx in this disease area. BD also has an option to exercise a commercial license in the future. The goal of this agreement is to identify markers that will ultimately form the basis for new Diagnomic(TM) tests for colon cancer. Diagnomic(TM) tests are molecular diagnostics that can describe a patient`s current medical condition and provide prognostic and therapeutic information. (Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) "Together, MPMx and BD have made the industry`s largest commitment to the development of Diagnomic(TM) products in oncology. We are pleased to be including colon cancer in the areas of cancer for which Diagnomic(TM) tests will potentially be developed," said Kenneth Conway, president of Millennium Predictive Medicine. "Diagnomic(TM) tests may play an important role in combating colon cancer because of the tremendous value of early detection of this disease." "We have established a strong relationship with MPMx and are delighted to add a further opportunity to address an area of critical unmet medical need," said Caroline Popper, M.D., M.P.H., General Manager, BD. "We look forward to working with MPMx`s assets in the field of colon cancer and potentially moving forward to develop novel diagnostic tests." Colon Cancer According to the American Cancer Society, about 93,800 new cases of colon cancer will be diagnosed in the United States this year, and colon cancer will cause 47,700 deaths. Nine out of ten people whose colorectal cancer is found and treated at an early stage live at least five years. Like all other cancers, colon cancer causes cells in the body to change and multiply beyond normal ranges. The exact cause of colon cancer is not yet known, but scientists have identified certain risk factors, including family history of the disease, smoking, a personal history of inflammatory bowel disease, obesity, inactivity and age. The public`s reluctance to undergo screening tests is currently a significant barrier to early disease identification. Previously Existing Alliance In February 1999, MPMx entered into a strategic alliance in the diagnostics field with BD. The five-year, genomics-based research collaboration focuses on the following areas of oncology: melanoma, cervical, breast, ovarian, uterine and prostate. MPMx will supply clinically-validated markers to BD and the two companies will jointly determine which tests, from among staging, screening and pharmacogenomics, will be developed for each type of cancer included in the alliance. BD, a global medical technology company, headquartered in Franklin Lakes, New Jersey, manufactures and sells a broad range of medical supplies and devices and diagnostics systems for use by healthcare professionals, medical research institutions, industry and the general public. MPMx, a wholly-owned subsidiary of Millennium Pharmaceuticals, Inc., is focused on the development of Diagnomic? and pharmacogenomic products and services. MPMx is headquartered in Cambridge, Massachusetts. Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium and its affiliates currently employ more than 1,000 people. This press release contains "forward-looking statements." These statements include descriptions of Millennium`s operational plans, expectations about future earnings and other results of operations, views of future industry or market conditions, and other statements that include words like "may," "expects," "believes," and "intends," and that describe opinions about future events. Known and unknown risks may cause Millennium`s actual results and performances to be materially different from those expressed or implied by these statements. Some of these risks are: uncertainties relating to unanticipated difficulties and delays relating to gene identification, drug discovery and clinical development processes; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and regulatory approval; and uncertainties relating to the ability of Millennium and its affiliates to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and more fully explained under the heading "Risk Factors That May Affect Results" in the annual report on Form 10-K filed by Millennium with the Securities and Exchange Commission on February 25, 2000. KANN MIR JEMAND EINE KURZE ZUSAMMENFASSUNG DIESER NEWS SCHREIBEN, DA MEINE ENGLISCH KENNTNISSE ZU WUENSCHEN UEBRIG LASSEN! DANKE IM VORAUS. |
|
| aus der Diskussion: | Quartalszahlen von Millennium |
| Autor (Datum des Eintrages): | luna2000 (19.07.00 22:06:20) |
| Beitrag: | 5 von 9 (ID:1358509) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |